Skip to main content

Table 1 Case reports of cardiotoxicity with gemcitabine monotherapy

From: Gemcitabine-induced cardiomyopathy: a case report and review of the literature

Author

Demography

Dose of gemcitabine

Duration of treatment

Side effect

History of CAD

Timing

Outcome

Probability

Ozturk et al.[17]

59F with metastatic leiomyosarcoma

900mg/m2

8 days

Coronary vasospasm

Yes

30 minutes after infusion

Survived. Gemcitabine therapy stopped

Strong

Bdair et al . [18]

43F with metastatic NSCLC

1000mg/m2

7 weeks

NSTEMI VT

Yes

3 days after infusion

Survived. Gemcitabine therapy stopped

Weak

Kalapura et al . [19]

54M with metastatic pancreatic cancer

1900mg

5th cycle

NSTEMI

No CAD, no risk factors

6 hours after infusion

Survived. Recurrent symptoms with 7th cycle

Strong

Tayer-Shifman et al.[20]

67F with metastatic ductal carcinoma of breast

1000-1400mg/m2

3rd cycle

SVT/AVNRT

No CAD, no risk factors

Hours after infusion

Survived. Gemcitabine therapy stopped

Strong

Santini et al.[21]

78M with pancreatic adenocarcinoma

NK

1st cycle

AF

History of AF in the past

18-22 hours after the infusion

Survived 6 total episodes of AF 18-22 hours after the infusion

Strong

Ferrari et al.[22]

72F with metastatic lung adenocarcinoma

1200mg/m2

1st cycle

AF

No history of AF

18 hours after the infusion

Survived 3 total episodes of AF each after 18 hours of infusion

Strong

Ferrari et al.[22]

73F with NSCLC

1200mg/m2

3rd cycle

AF

No history of AF

12 hours after the infusion

Survived. Gemcitabine stopped

Strong

Tavil et al.[23]

65M with NSCLC

1200mg/m2

2nd cycle

AF

No history of AF

7 hours after the infusion

Gemcitabine stopped

Strong

Ciotti et al.[24]

70M with metastatic pancreatic adenocarcinoma

NK

1st cycle

AF

No history of AF

6 days after the infusion

AF recurred with further therapy

Strong

Yajima et al.[25]

82F with advanced pancreatic carcinoma

16, 800mg-total dose

Two years of treatment

HF

NK

2 years

Gemcitabine stopped

Weak

Khan et al. [present case]

56M with pancreatic adenocarcinoma

1000mg/m2

Two cycles (2 months)

CMP/HF

No prior history of CHF/CAD

2 months

Gemcitabine stopped, partial recovery

Strong

  1. CAD, coronary artery disease; F, female; NSCLC, non-small cell lung cancer; NSTEMI, non-ST elevation myocardial infarction; VT, ventricular tachycardia; M, male; SVT, supraventricular tachycardia; AVNRT, AV nodal re-entrant tachycardia; NK, not known; AF, atrial fibrillation; HF, heart failure; CMP, cardiomyopathy; CHF, congestive heart failure.